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Abstract: Growth hormone (GH), also known as somatotropin, is a peptide hormone that is 
synthesized and secreted by the somatotrophs of the anterior pituitary gland. The main action of 
GH is to stimulate linear growth in children; however, it also fosters a healthy body   composition 
by increasing muscle and reducing fat mass, maintains normal blood glucose levels, and promotes 
a favorable lipid profile. This article provides an overview of the normal pathophysiology of GH 
production and action. We discuss the history of GH therapy and the development of the current 
formulation of recombinant human GH given as daily subcutaneous injections. This paper reviews 
two of the longest standing FDA-approved indications for GH treatment, GH deficiency and 
Turner syndrome. We will highlight the pathogenesis of these disorders, including presentations, 
presumed mechanism(s) for the associated short stature, and diagnostic criteria, with a review 
of stimulation test benefits and pitfalls. This review also includes current   recommendations for 
GH therapy to help maximize final height in these children, as well as data demonstrating the 
efficacy and safety of GH treatment in these populations.
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Introduction
Growth hormone pathophysiology
Growth hormone (GH), also known as somatotropin, is a peptide hormone that is 
synthesized and secreted by the somatotrophs of the anterior pituitary gland.1 The 
main effect of GH is to promote linear growth in children. Its secretion is   pulsatile and 
primarily controlled by GH-releasing hormone (GHRH) (stimulatory), by   somatostatin 
(inhibitory), and, to a lesser degree, by ghrelin (stimulatory).2 A complex feedback 
system involving insulin-like growth factor-1 (IGF-1), leptin, ghrelin, free fatty acids, 
and the central nervous system regulates GH secretion.3,4 When released, GH binds to 
its receptor in the liver and cartilage, leading to production of IGF-1, which through 
endocrine and paracrine/autocrine mechanisms, then stimulates linear bone growth.5 
GH acts at the epiphysis (growth plate) to increase linear growth by   promoting 
  differentiation of prechondrocytes and expansion of osteoblasts.6,7 Both GH and IGF-1 
are needed to stimulate normal linear growth; however, the exact cellular targets for 
the direct effects of GH remain ill-defined in complex tissues such as the growth 
plate. The contribution of the direct and indirect actions of GH is controversial.8 It 
is known that, when GH binds to its receptor, it causes dimerization of the receptor, 
which leads to interaction of the receptor with janus kinase 2 (JAK2) and subsequent 
tyrosine phosphorylation of JAK2 and the GH receptor itself, followed by changes in 
the phosphorylation of the signal transducer activator of transcription (STAT) pathway 
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Figure 1 Growth hormone–iGF-1 axis.  
Abbreviations: GHRH, growth hormone releasing hormone; GH, growth hormone; GHBP, growth hormone binding protein; iGF-1, insulin-like growth factor-1; 
iGFBP-3, insulin-like growth factor binding protein-3; ALS, acid-labile subunit; STAT5b, signal transducer activator of transcription pathway 5b.
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which then stimulates target gene transcription. In the liver, 
GH receptor activation leads to an increased production of 
IGF binding protein-3 (IGFBP-3) and acid-labile subunit 
(ALS) which bind IGF-1 in a ternary complex thereby 
increasing its half-life9 (Figure 1).
GH actions
The endogenous and exogenous effects of GH involve four 
main areas. First, GH stimulates linear bone growth as 
  discussed above. Second, GH increases bone mass. Third, 
GH acts on adipose tissue to increase lipolysis, inhibit 
  lipoprotein lipase, stimulate hormone-sensitive lipase, 
decrease glucose transport, and decrease lipogenesis. Fourth, 
GH acts on muscle to increase transport of amino acids and 
may affect muscle fiber distribution.10 Thus, in patients with 
GH   deficiency (GHD), GH therapy not only increases linear 
growth velocity, but also promotes maintenance of healthy 
body composition (increased muscle and reduced fat mass), 
normal blood glucose levels, and a favorable lipid profile.
Pharmacology of GH
GH medication development
Multiple advances in the treatment of GHD have been made 
in the more than 50 years since treatment began in 1958.11 
Initially, human pituitary GH, derived from pituitary glands 
of recently deceased humans, was used only for severely 
GH-deficient children. Limited supply of the hormone and 
transmission of Creuzfeldt-Jacob Disease in some patients 
after treatment led to discontinued use of human cadaveric 
GH in 1985.12 The structure of GH was determined in 1972 
and this led to research and development of synthetic GH. 
In 1979, Goeddel et al expressed the gene for human GH 
in Escherichia coli allowing the bacteria to produce human 
GH in large quantities.13 In 1985, Genentech became the 
first company to make recombinant human GH (rhGH), also 
known as somatotropin.14
GH has two known isoforms, weighing 22 kD and 
20 kD; their structures are shown below (Figure 2). The 
first   available rhGH, protropin, was a polypeptide hormone 
produced by inclusion body recombinant DNA technology. 
Protropin had 192 amino acids and a molecular weight of 
22 kDa. This molecule contained the identical sequence of 
191 amino acids found in native pituitary hormone with 
the addition of a methionine (met-GH) on the N-terminus, 
initially required to facilitate the biosynthetic process using 
E. coli. Use of met-GH was associated with the development 
of antibodies, although typically not of a growth-neutralizing 
variety.15 All current forms of rhGH used in practice today Clinical Pharmacology:   Advances and Applications 2010:2
Table 1 Food and Drug Administration (FDA) indications for 
growth hormone (GH) treatment16
Year of initial 
FDA approval
Indications for GH treatment
1985 Pediatric growth hormone deficiency
1993 Growth failure secondary to chronic renal 
failure up to the time of renal transplantation
1996 Adult growth hormone deficiency 
1996 Hiv wasting in adults
1996 Turner syndrome 
2000 Prader-willi syndrome 
2001 Small for gestational age
2003 idiopathic short stature
2003 Short bowel syndrome
2006 SHOX gene deficiency
2007 Noonan syndrome
Figure 2 Primary structure of human growth hormone (GH) and its isoforms. The main chain represents 22K-GH (GH-N). The sequence indicated by the bold line from 
residue 32–46 is deleted in 20K-GH. The black dot at the amino terminus denotes the acyl group in N-acylated GH. The two asterisks denote the deamidated residues in 
desamido-GH forms. The amino acid designations next to the main chain denote the residues that are changed in GH-v (placental GH). The tree structure at residue 140 
indicates the glycosylation site in glycosylated GH-v. Reprinted with permission from Baumann GP. Growth hormone isoforms. Growth Horm IGF Res. 2009;19(4):333–340.2 
Copyright © 2009 elsevier.
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have the identical 191 amino-acid sequence found in 
native pituitary hormone.16 There are no clinically relevant 
  antibody reactions to current rhGH as it mimics the human 
GH structure.
GH indications
There are 11 US Food and Drug Administration (FDA)-
approved conditions to date that have been shown to benefit 
from rhGH therapy (Table 1). The dose used varies by age, 
physiology, indication, response to treatment, and individual 
practice preferences of the prescribing   physician. In addition, 
the range of doses, at least for pediatric   indications, also stems 
from results of clinical trials in which initial dosage choices 
were based on the presence of GH deficiency (lower doses) or 
(presumed) GH resistance (higher doses).   Furthermore, dose 
selection is also sometimes driven by regulations set forth by 
third-party payers. Review of GH products   available in the US 
reveals that no single brand is approved for all indications.16 
However, since the active medication,   somatotropin, is the 
same in each product, many physicians feel comfortable 
using any approved product for any   appropriate indication. 
Similarly, in other parts of the world, GH products are often 
used   interchangeably. The drug approval process in Europe 
via the European   Medicines   Evaluation Agency (EMEA) is 
likely to approve new   preparations of rhGH for   indications 
approved for “biosimilar” products. It is suggested by Ranke 
et al that this type of approval, if granted, should be used 
with caution as safety and efficacy may be different between 
  medication brands even though the active medication is Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
114
Southern Reh and Geffner
  similar.17 Ultimately, the informed physician and often the 
insurance company will influence the choice of the GH 
product selected for each patient.
This review will provide an overview of two of the 
longest-standing indications for GH treatment, GHD and 
Turner syndrome (TS), in which we will highlight the 
  pathogenesis of these disorders, including presentation, 
presumed mechanism(s) for the associated short stature, 
diagnostic criteria, and current recommendations for GH 
treatment, including the efficacy and safety of GH use.
Growth hormone deficiency
Background – presentation, causes,  
and diagnosis
GHD normally presents with short stature, poor height 
  velocity, relative weight preservation, and delayed bone 
age. In infancy, affected children may also manifest 
  hypoglycemia, prolonged jaundice with or without giant 
cell hepatitis, and   microphallus in males. The estimated 
incidence of GHD ranges from 1:4000 to 1:10,000. 
Causes of GHD can be divided into two main   categories: 
  congenital and acquired. Congenital causes can be 
  further subdivided into genetic defects18 or anatomical 
  abnormalities (eg,   hypothalamic-pituitary stalk transection, 
optic nerve   hypoplasia, and cranial anomalies including 
holoprosencephaly).19 Acquired etiologies of GHD include 
suprasellar tumors (most commonly, craniopharyngioma), 
inflammatory processes, infections of the central nervous 
system, head trauma,20 post-surgical, post-radiation,21,22 
and psychosocial deprivation.23 Although there are many 
known causes of GHD, most cases appear to have an 
idiopathic basis. Clinically it is important to rule out all 
other causes of GHD before referring to the etiology of the 
condition as idiopathic. GHD is most often a secondary 
  phenomenon resulting from a hypothalamic abnormality 
(ie, low   concentrations of GHRH or an inability of GHRH 
to reach the pituitary) or, less   frequently, from a primary 
disorder of the pituitary gland leading to reduced secretion 
of GH. GH secretion from the pituitary gland is dependent 
on the sleep-wake cycle and, therefore, measurement of 
random serum levels of GH is not clinically useful. Thus, 
if the diagnosis of GHD is suspected based on poor height 
velocity, typically the serum concentrations of the GH 
surrogates, IGF-1 and IGFBP-3, are measured to screen 
for GHD.5,24 If these levels are found to be low (especially 
IGF-1), then a GH stimulation test is commonly performed. 
In most countries, diagnostic criteria for GHD are based on 
a combination of auxological data and peak GH responses 
to two GH provocative tests. Criteria for starting treatment 
are listed in Table 2.25
Over the years, multiple medications, capitalizing on 
either the known pharmacological regulation of endogenous 
GH secretion or on the physiology of glucose counter-
  regulation in response to hypoglycemia, have been used to 
provoke GH secretion, including l-dopa, insulin, glucagon, 
clonidine, arginine, and GHRH (no longer available).26 Each 
has possible side effects and reasons for use. The first of 
these was the insulin tolerance test (ITT) that stimulated GH 
by inducing hypoglycemia. The advantage of the ITT is that 
it allows for simultaneous assessment of the ACTH-cortisol 
axis which should also respond to hypoglycemia, but the risk 
of severe hypoglycemia during the test is   significant.27 Many 
pediatric endocrinologists do not use ITT for this   reason. The 
glucagon stimulation test increases GH   secretion by   causing 
an initial rise in the plasma glucose level to ∼150 mg/dL, 
which, in turn, simulates the body to produce insulin to 
decrease the plasma glucose back to normal, with a frequent 
nadir of ∼60 mg/dL. This physiologically controlled   reduction 
in plasma glucose concentration from slightly above normal to 
low normal will stimulate GH secretion in non-GH-deficient 
individuals. There is still a risk of mild hypoglycemia, but 
severe episodes are far less frequent than occur with the ITT. 
Clonidine stimulates GH secretion by mimicking the normal 
α-adrenergic   regulation of GH release from the pituitary, but 
has the risk of   inducing hypotension. Since there are risks to 
performing all of these tests, they should always be performed 
under the direct supervision of a pediatric   endocrinologist and 
trained   nursing staff. An abnormal response to stimulation 
testing to all agents (except GHRH) is defined arbitrarily as 
a peak GH level , 10 ng/mL. This definition is controver-
sial because many patients (∼75%) with apparent idiopathic 
isolated GHD diagnosed in   childhood will have normal GH 
responses when retested off GH treatment as adolescents dur-
ing the transition period or as adults.28 Due to the limitations 
of the stimulation testing, two failed GH stimulation tests are 
often required to make a diagnosis of GHD. This is part of 
the diagnostic criteria for GHD in many countries, as well 
as a requirement of insurance companies prior to granting 
authorization for GH treatment.
Treatment of GHD
Diagnosis in GHD is based on both clinical and biochemical 
parameters as described above. Historically, GH preparations 
were injected intramuscularly to allow complete   absorption 
while limiting antibody formation. However, once it was 
shown that subcutaneous (SC) injections were equally Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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  effective, less painful, and without side effects,29 this became 
the preferred route of administration. The recommended 
frequency of GH injections has also changed over the years. 
Originally, pituitary GH was given 2 days per week, but 
then it was discovered that dividing the weekly dose into 
3 injections yielded better growth rates.30 It was ultimately 
  discovered that daily injections led to even better growth 
rates31 which has been confirmed by many studies.32  –34 Serum 
levels of GH reach a supraphysiological maximum 2 to 
6 hours after a SC injection and then fall by about 12 hours.35 
Injections in the evening have been shown to result in a more 
physiological pattern of glucose and protein metabolites than 
if GH is given in the morning.36 Therefore, rhGH is currently 
used as a once-daily SC injection, typically given late in the 
evening in an attempt to mimic the normal sleep-entrained 
(nychtemeral) secretory pattern of endogenous GH.35
The physiological prepubertal production rate of GH 
is 0.02 mg/kg/day (0.06 IU/kg/day) which increases two 
to four times during puberty. The goal of treatment is to 
mimic these levels while minimizing side effects. There is 
a wide range of recommended dosing of GH   internationally 
for the treatment of GHD. GH dose ranges between 0.5 
to 0.7 IU/kg/week (0.17 to 0.23 mg/kg/week) in most 
  countries.25 The highest doses are used in the US and range 
from 0.17 to 0.35 mg/kg/week, while the smallest doses 
are used in Japan (0.5 IU/kg/week).25 Data from a study by 
Tanaka using an international survey showed a range of initial 
GH treatment doses by country (Table 3).
Table 2 Criteria for initiation of growth hormone (GH) treatment in children with GH deficiency25
Country Origin of guidelines Criteria
    Height Bone age  Growth velocity Peak GH in provocative test
Australia Australia Pediatric 
endocrine Group
, 1st  
percentile, 1st to  
10th percentile
Boys , 15.5 yr  
Girls , 13.5 yr
, 25th percentile for 
bone age
, 10 mU/L on 2 tests
Canada Canadian Advisory 
Group
, 3rd percentile , –2 SD , 3rd percentile for 
bone age
, 8 ng/mL on 2 tests
France Health Authority , -2 SD , -1 SD or , 4 cm/yr , 10 ng/mL on 2 tests
Germany working Group  
of Pediatric  
endocrinologists
short stature delayed , 25th percentile for 
bone age
, 10 ng/mL on 2 tests,  
or , 10 ng/mL on 1 test  
with low iGF-i and iGFBP-3
israel National GH 
Committee
Boys , 15 yr 
Girls , 13 yr
, 1.5 SD for . 6 mo , 8 ng/mL on 2 tests
Japan Study Group  
of Hypothalamic  
Pituitary Disease  
of Ministry of  
Health and welfare
Boys , 16 yr 
Girls , 14 yr
 -1.5 growth velocity 
SD for chronological age 
during preceding 2 yr
, 10 ng/mL on 2 tests
Netherlands GH Advisory Group delayed , 10 ng/mL on 2 tests
Spain GH Advisory Group , 10 ng/mL on 2 tests
Sweden GH Advisory Group , 32 mU/L polyclonal antibody
Taiwan Society of Pediatric 
endocrinology
organic Boys , 16 yr  
Girls , 14 yr
, 4 cm/yr , 10 ng/mL on 2 tests
United States Lawson wilkins 
Pediatric endocrine  
Society77
, -2.25 SD for  
age or , 2 SD  
below mid- 
parental height
, 2 SD below  
mean age
, 25th percentile for 
bone age
Abbreviations: iGF, insulin-like growth factor; SD, standard deviation.
Table 3 Growth hormone (GH) treatment doses used in GH 
deficiency25
Country Dosage of GH used
Australia 0.5–0.7 iU/kg/wk (14–22 iU/m2/wk)
Canada 0.18–0.24 mg/kg/wk (0.5–0.72 iU/kg/wk)
France 0.6–0.9 iU/kg/wk
Germany 0.5 iU/kg wk, can be increased based on response
israel no limitation
Japan 0.5 iU/kg wk
Netherlands 14 U/m2/wk (0.5 iU/kg/wk), can be  
increased based on response
Spain prepubertal 0.5 iU/kg/wk, puberty  
0.5–0.6 iU/kg/wk
Sweden 0.1 U/kg/day (0.7 iU/kg/wk)
Taiwan 0.7 iU/kg/wk
United Kingdom 14–20 iU/m2/wk, 0.5–0.7 iU/kg/wk
United States 0.17–0.35 mg/kg/wk (0.525–1.05 iU/kg/wk)Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Because of higher secretion of both GH and IGF-1 
during normal puberty, the concept of higher replacement 
doses d  uring puberty has surfaced. Some studies   suggest that 
patients with GHD may achieve greater pubertal growth if 
treated with higher doses than are typically   recommended for 
prepubertal children to mimic normal pubertal physiology.37–39 
The results of these small-scale studies were sufficient to 
engender FDA approval for use of higher doses of GH   during 
puberty in children with GHD (up to 0.7 mg/kg/week). 
Monitoring with serum IGF-1   levels   specific for age, 
gender, and Tanner stage must be used to determine the 
safe and optimal GH dose in puberty.40   Currently, many 
  endocrinologists continue treatment through puberty with 
close monitoring of height velocity, bone age, serum IGF-1 
levels, and pubertal progression to ensure the maximal effect 
of treatment. In most countries, GH therapy is continued 
until height velocity decreases to ,2.5 cm/year and/or until 
the bone age is advanced to between 13 to 15 years for girls 
and 15.5 to 16 years for boys.25 It is now   recommended that 
most patients with childhood-onset GHD be retested for 
GHD (except perhaps those with prior clear-cut, permanent 
GH deficiency, ie, those with multiple pituitary hormone 
deficiencies and/or an abnormal head MRI) after they have 
reached final height. Newer data suggest that patients with 
idiopathic isolated GHD should be retested when they start 
puberty to determine if they are still GH-deficient. If they 
pass the repeat GH stimulation testing at the beginning of 
puberty, then they may be able to reach final adult height 
even if GH treatment is discontinued.41
The transition period between adolescence and adulthood 
is a unique time to reassess the need for GH treatment. In 
the past, use of GH in children with GHD was continued 
until epiphyseal fusion occurred; however, there are newer 
data to suggest that GH has important benefits on bone 
  mineralization, lean body mass,42–44 and cardiac risk factors, 
ie, abnormal lipid profile and excess visceral adiposity.45,46 
Based on these metabolic benefits, it is suggested that 
adults may also benefit from GH treatment. For adults with 
  persistent GHD, the effective dose is one-sixth to one-third 
less than that needed for growing children and adolescents. 
In order to establish which adults may benefit from continued 
GH therapy, it is important to determine who is most likely 
to have persistent GHD. Over 90% of those patients with 
multiple pituitary hormone deficiencies and/or clear-cut 
evidence of organic pituitary disease will have persistent 
GHD as adults. On the contrary, 67% up to 75% patients with 
idiopathic isolated GHD in childhood will pass repeat GH 
testing during the transition phase.28,47 The exact reason for 
the discrepancy is uncertain, but may result from   variations 
in testing protocols, the lack of   reproducibility of GH 
  provocative testing, variation in GH assay   methods,   failure 
to use sex-steroid priming, and the effects of   nutrition.48 
Thus, it is recommended that most patients with isolated 
GHD be retested, while those with well-delineated organic 
causes need not be.
Efficacy of GH treatment in GHD
As stated above, the major goal of GH treatment is to provide 
the short child with improvement in height velocity in order 
to attain a final height within the range that is expected for 
his or her family and, if possible, within the normal range of 
the   general population. We will first discuss the efficacy of 
  treatment as it pertains to GHD. Later we will review the safety 
of use of rhGH in children, as it is imperative to understand 
and minimize the risk of any potential   undesirable effects.
Multiple studies have assessed the efficacy of rhGH use 
in children with GHD. Evaluation of patients with GHD 
shows that multiple factors affect final height: number of 
injections per week, duration of treatment, age at diagnosis, 
and, most of all, genetic height potential. The data from the 
Kabi   International Growth Study (KIGS) show that children 
with GHD can attain improvement in final height with GH 
treatment increasing +1.6 standard deviation (SD) from 
baseline and falling within range for family height genetics.49 
The Swedish analysis of KIGS data showed that subjects 
with severe GHD (defined as peak GH , 3.3 ng/mL) were 
shorter than those with partial GHD, even when   corrected 
for mid-parental height, but there was no significant dif-
ference between final height in each group.50 Data from 
the National Cooperative Growth Study (NCGS), in which 
approximately 20,000   children receiving rhGH have been 
tracked, show that 40% had idiopathic GHD, while 13.8% 
had organic GHD. For subjects who were treated for 7 
consecutive years, the mean height SD score increased by 
2.5 SD in isolated GHD and by 2.0 SD in organic GHD.51 
To help determine the   optimum GH treatment strategy for 
children with GHD (and TS),   mathematical models have 
been   developed based on   clinical data from a large number 
of   subjects. These   prediction   models are based on known 
  clinical data, i  ncluding birth status, genetic potential, 
  laboratory data, and GH   treatment schedule. The model 
explains about 61% of the variability in the growth response 
to GH. It was noted that a better response is seen in those 
subjects with the f  ollowing features: lower peak GH level, 
younger age at the onset of treatment, larger gap between the 
subject’s height and   mid-parental target, higher GH dose, and Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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higher body weight and/or birth weight.51,52 Further model 
analysis is being   developed to optimize GH treatment in 
children with GHD.
Turner syndrome
Background
TS is one of the most common causes of short stature in 
females. TS has an incidence of 1 in 2000 to 1 in 2500 live 
female births.53 It is a sporadic genetic disorder caused by a 
complete (monosomy) or partial lack of one X   chromosome.16 
Affected females typically present in one of five ways: 
1) prenatally with a diagnostic chromosome analysis on 
amniocentesis (assessed for unrelated reasons, eg, advanced 
maternal age); 2) at birth, with lymphedema of the hands 
and feet and other dysmorphic features (eg, webbed neck, 
with or without associated cardiac abnormalities; 3) during 
the pre-pubertal age range with short stature and subnormal 
height velocity with or without subtle dysmorphic features; 
4) in adolescence with absent breast development and/or 
primary amenorrhea; or 5) in adulthood during evaluation 
for infertility.
Although the primary abnormalities in this disorder are 
short stature/poor growth velocity in nearly 100% and   primary 
ovarian failure in ∼85% of girls with TS, other   stigmata may 
be present at varying (but fairly low)   frequencies,   including 
webbed neck, low-set pinnae, low   posterior hair line, 
  shield-shaped chest, widely-spaced nipples, and increased 
carrying angles (cubitus valgus). Many girls with TS have 
left-sided cardiac defects, such as marked tortuosity or 
ectasia of aortic arch, isolated   non-stenotic bicuspid aortic 
valve, coarctation of the aorta, and   hypoplastic left heart 
syndrome along with non-functional renal   abnormalities, 
  including horseshoe-shaped kidneys and duplicated 
  collecting systems.
Growth failure is the most common feature of TS. The 
growth pattern of girls with TS can be divided into four 
phases as described by Ranke17: 1) intrauterine growth is 
slightly retarded; 2) normal growth occurs up to a bone age 
of about 3 years, with a tendency to compensate for the loss 
in growth during intrauterine life; 3) stunting of growth is 
progressive and severe during the subsequent childhood 
years; and 4) the growth phase is prolonged after a bone 
age of about 10 years, when puberty normally starts and 
estrogen production normally increases, but, despite this lack 
of endogenous estrogen-induced epiphyseal fusion in most 
cases, total height gain is nonetheless markedly reduced. 
Similarly, Davenport et al described growth in girls with TS 
showing that mean height SD score fell from -0.5 at birth 
to -1.5 at age 1 year and to -1.8 at age 1.5 years. Growth 
curves from this study revealed that growth failure was due 
to: (a) mild growth retardation in utero, (b) slow growth 
  during infancy, (c) delayed onset of the childhood component 
of growth, and (d) slow growth during childhood.54 Untreated, 
the average height of women with TS is 143 cm (4 ft 8 in) 
which is approximately 20 cm (8 in) below the average height 
of women in the US.55
etiology of short stature
The etiology of short stature and skeletal abnormalities 
in TS results in part from haploinsufficiency of the short 
stature homeobox-containing (SHOX) gene located in the 
  pseudo-autosomal region of the X-chromosome.56 SHOX 
deficiency was identified in girls with TS as well as a small 
subset (∼1% to 2%) of children with “idiopathic” short 
stature.56 The SHOX gene is an important controller of 
bone growth that regulates chondrocyte differentiation and 
  maturation.57 It is now thought that SHOX haploinsufficiency 
can result not only in short stature, but may play a role in the 
other skeletal features associated with TS, including cubitus 
valgus, short metacarpals, Madelung deformity, high-arched 
palate, and short neck.58
In order to treat a child with TS with GH, the diagnosis 
of TS must be confirmed, but GH stimulation testing is 
  ordinarily not necessary. GH secretion in TS has been studied 
to determine if an abnormality of secretion affects height. An 
Italian study by Cavallo et al59 showed that impairment of GH 
secretion is frequent in girls with TS, especially if they are 
obese (a finding not unique to the TS population), and that 
impairment of GH secretion is not related to karyotype or 
spontaneous thelarche and/or pubarche or height. The authors 
concluded that although GH secretion (both GH reserve 
and mean spontaneous nocturnal secretion) is abnormal, it 
did not influence height in TS patients. Thus, stimulation 
t  esting in patients with TS is unnecessary.59 rhGH therapy 
has been approved in the US for use in children with TS 
since 1996. Efficacy of GH in TS will be discussed later, but 
it is interesting to note that patients with SHOX deficiency, 
not associated with TS, also respond to GH. Final height in 
isolated SHOX deficiency is similar to that in patients with 
TS.60 Isolated SHOX deficiency was also approved by the 
FDA as an indication for GH treatment in 2006.
Treatment of TS
The FDA-approved dose of rhGH for treatment of 
girls with TS in the US is from 0.36 mg/kg/week up to 
0.46 mg/kg/week. Unlike for patients with GHD, there is no Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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approved step-up in rhGH dose during the pubertal age by 
any governmental regulatory agency. In Japan, low-dose GH 
treatment at 0.175 mg/kg/week was used previously, but, as 
of December 1999, a higher dose of 0.35 mg/kg/week was 
approved.51,61 A prospective study of GH dosing in TS by Van 
Pareren et al examined 3 groups over a 4-year course of GH 
treatment. Group A was given GH at a dose of 4 IU/m2/day 
(∼0.045 mg/kg/day) for all 4 years, group B had an increase in 
dosage from 4 IU/m2/day to 6 IU/m2/day (∼0.068 mg/kg/day) 
in the second year, and group C had the same doses as in 
group B in years 1 and 2, and then was increased further in 
year 3 to 8 IU/m2/day (∼0.09 mg/kg/day). Results showed 
that Group A had the shortest final height of 157.6 ± 6.5 cm, 
while groups B (162.9 ± 6.1) and C (163.6 ± 6.0) showed 
a   significant increase in height compared to Group A 
(P , 0.001). Groups B and C were not statistically different 
from one another.62 These results showed that higher doses 
of GH in girls with TS improve final height.
Estrogen is critical for bone growth and epiphyseal 
  maturation in both male and females, especially during 
puberty. The delicate balance between GH and estrogen 
becomes critical in patients with TS, most of whom have 
gonadal failure and require estrogen therapy to induce 
  pubertal changes. While historically estrogen replacement 
has been intentionally delayed in girls with TS to maximize 
height through later epiphyseal closure (including those 
girls receiving GH), the current trend is to begin estrogen 
replacement at a younger age, more akin to that when 
  gonadarche occurs in normal girls. Although improvement 
in height outcome is still desired with this approach, it may 
also allow for normal bone mineral accretion and better 
psychosocial adaptation with normally timed puberty.63 In 
the study by Quigley et al64 patients with TS were treated 
with GH (at either 0.27 or 0.36 mg/kg/week) in combination 
with either pacebo or low-dose estrogen (100 ng/kg/day of 
ethinyl estradiol) to determine change in SD scores from 
baseline to near-final height. The two groups receiving 
higher GH doses with and without estrogen showed final 
heights of 149.1 ± 6.0 cm and 150.4 ± 6.0 cm, respectively. 
The near-final heights of those treated with lower GH doses 
were 145.1 ± 5.4 cm and 149.9 ± 6.0 cm, respectively. The 
change in SD scores between subjects with GH and   estrogen 
treatment and those with GH and placebo was 0.7 ± 0.1 
vs 0.9 ± 0.1 (P = 0.11). The difference in standard deviation 
score (SDS) was not statistically significant. It is unclear from 
this study if   estrogen treatment improves, compromises, or 
has no effect on final height.64 The treatment paradigm shift 
toward earlier introduction of estrogen, has been facilitated 
by the availability of transdermal estrogen patches, which can 
be cut to provide very small doses of estrogen. The delicate 
balance of estrogen replacement for pubertal development 
and GH treatment to optimize height must be individualized 
for each patient by the pediatric endocrinologist.
Efficacy of GH treatment in TS
Patients with TS benefit from GH therapy with   improvement 
in final height. The degree of benefit depends on the age at 
which therapy begins, dose given, duration of treatment, 
mid-parental target height, and when concurrent therapy with 
estrogen is used to induce puberty. The Ranke   prediction 
model for TS incorporates data from Kabi International 
Growth Study (KIGS), including the above factors, into 
a mathematical model to help determine the association 
between the clinical parameters and near-final height.51,52,65 
This analysis showed that younger age at onset of treatment, 
taller parents (higher mid-parental target height), and later 
onset of puberty were associated with taller near-final height 
compared to projected, ie, from 146.1 cm to 151.0 cm.65 The 
Toddler Turner study prospectively compared the short-term 
height outcomes of girls started on rhGH between the ages 
of 9 months and 4 years to see if there were a significant 
  difference in height compared to patients with TS of the 
same age randomized not to receive GH treatment. Those 
given rhGH at 0.35 mg/k/week had statistically significant 
improvement in mean height SDS increasing by 1.1 SDS 
(from -1.4 ± 1.0 to -0.3 ± 1.1), while those without treatment 
had a decrease in height SDS of 0.5 SDS from -1.8 ± 1.1 
to -2.2 ± 1.2, (P , 0.0001).66 Whether these preliminary 
  observations will translate into better adult height than 
  typically has been achieved in girls with TS (with a mean 
age of start of treatment in clinical practice still not until 9 
years in the US) is being investigated in the 10-year follow-up 
study known as the Turner Tween Study. Final height analysis 
done by Morin et al in a cohort of 25 girls who were followed 
for median 3.8 years (2.1 to 10.3 years) showed height gain 
in the GH treatment group that was 11.2 ± 3.7 cm over that 
originally predicted, ie, 5 feet vs 4 ft 8 in. Of the 25 girls, 
only one (4%) was projected to meet the third percentile 
before GH treatment, compared to follow-up after treatment 
when 14 of 25 girls (56%) had final heights on the third per-
centile.67 A randomized, controlled trial of GH treatment of 
154 girls with TS was performed in Canada. At study entry, 
girls were 7 to 13 years old. They were   randomly assigned 
to be given GH as six SC injections/week at a total dose 
of 0.3 mg/kg/week or to a control group that received no 
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were 147.5 ± 6.1 cm vs 141 ± 5.4 cm for controls (P , 0.001). 
Mean height gain due to GH was estimated to be 7.2 cm 
(confidence interval, 6.0 to 8.4) at study completion.68 The 
final height outcomes in the Dutch study for treatment in 
TS were much more favorable. This study included younger 
children (ages 2 to 11 years) at baseline and was designed to 
study dose response. Girls were randomized into one of three 
groups: a) 4 IU/m2; b) 4 IU/m2 in the first year followed by 
6 IU/m2 thereafter; and c) 4 IU/m2 in the first year followed by 
6 IU/m2 in the second year, and 8 IU/m2 for the remainder of 
the study. Of  25 girls who completed the study, the mean final 
heights were 159.1 cm, 161.8 cm, and 162.7 cm in groups 
a, b, and c, respectively. The final height gain in each group 
was 12.5 cm, 14.6 cm, and 16.0 cm, respectively. These better 
results may be due to an overall higher dosing paradigm of 
GH employed, younger age at the beginning of treatment, 
and/or better genetic potential in the Netherlands.69 It is clear 
that GH therapy is beneficial to the height of girls with TS 
and, thus, guidelines for the treatment of patients with TS 
almost universally include treatment with GH.
Safety and side effects  
of GH treatment
Multiple studies have assessed the safety of rhGH use in 
children with GHD and TS. Overall, GH therapy is   relatively 
safe with the most common side effects being pain or 
  bruising at the injection site, mild headache, and muscle or 
joint pain. Rare, but serious, side effects can occur   including 
benign intracranial hypertension (pseudotumor cerebri), type 
2 diabetes mellitus (T2DM), and slipped capital femoral 
epiphysis (SCFE).
The reported incidence of benign intracranial hyperten-
sion is ∼27.7 per 100,000 treatment-years in children treated 
with GH.70 The incidence of benign intracranial hyperten-
sion in patients with idiopathic GHD is much less than in 
those with either congenital GHD or TS. Benign intracranial 
  hypertension typically presents with signs of increased intrac-
ranial pressure including severe headache, papilledema, visual 
changes, nausea, and/or vomiting. This generally occurs 
within the first 8 weeks of treatment. Therapeutic   lumbar 
puncture can be used to treat this condition which usually 
resolves with cessation of GH therapy. Often GH treatment 
can be resumed at a much lower dose with gradual escalation 
without recurrence of benign intracranial hypertension.
GH induces insulin resistance which increases the risk of 
developing T2DM during GH treatment. There is also a risk 
of worsening glycemic control in patients with pre-existing 
diabetes, either type 1 or type 2. Since glucocorticoids also 
reduce insulin sensitivity, it is important to carefully   monitor 
patients treated with both GH and glucocorticoids. In the 
NCGS, the subjects treated with both GH and   glucocorticoids 
had a slight increase in mean hemoglobin A1c levels, but 
glucose and insulin levels were not statistically different 
between the two groups.71 GH-induced IGF-1 secretion also 
inhibits the expression of 11 β-hydroxysteroid   dehydrogenase 
(11β-HSD1), which catalyzes the conversion of cortisone to 
cortisol. Therefore, GH therapy may decrease the amount of 
cortisol production. Replacement with GH should be done 
cautiously in patients subject to adrenal crisis who may also 
have ACTH deficiency.72 Similarly, in patients at risk for 
multiple pituitary hormone deficiencies, it has been shown 
that GH treatment can unmask hypothyroidism in a subset 
of patients.73
A large retrospective study done by Cutfield et al found 
that 0.36% of children treated with GH (85 of 23,333) had 
abnormal glucose metabolism, with 11 having type 1   diabetes 
(T1DM), 18 T2DM, and 14 impaired glucose tolerance. 
The incidence of T1DM in those treated with GH was not 
  different than the expected number in the general   population. 
However, the incidence of T2DM was six-fold higher than 
reported in those not on GH therapy.74 It is thought that 
genetically   predisposed individuals are more prone to this 
effect. If T2DM develops, it usually will resolve (at least 
temporarily) with discontinuation of GH therapy.
According to the KIGS analysis, the total incidence of 
SCFE is 73.4 per 100,000 treatment-years of children treated 
with GH.70 SCFE presents as lower extremity pain in the hip 
or referred to the knee, and often with an inability to walk. 
Plain x-ray films of the hips can confirm the diagnosis. If 
SCFE is present, surgical pinning is needed to stabilize the 
hip joint. This is more likely to occur in overweight children 
and is also typically seen early, within the first 8 weeks of 
initiation of treatment.
To assess the long-term safety of GH therapy, data 
entered into the NCGS between 1985–2006 were analyzed. 
In this study, 54,996 children treated with rhGH were 
followed and the overall incidence of targeted events of 
intracranial hypertension, T2DM, and SCFE, along with 
scoliosis, pancreatitis, and adrenal insufficiency was quite 
low (, 1%). The data were separated based on diagnosis and 
included 23,393 subjects with idiopathic GHD and 8,351 
with organic GHD, as well as 5127 with TS. The malignancy 
rate in IGHD was zero, but was 0.1% in both the OGHD 
and TS groups. The overall incidence of de novo malignan-
cies, including leukemia and intracranial and extracranial 
tumors, in children treated with GH, was not increased. Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Second neoplasms, in patients with previous cancer and 
irradiation, occurred at an increased rate compared to the 
amount expected for a population without GH treatment and 
with similar risk.75 No unusual safety signals were evident 
in girls with TS treated with rhGH.
Patient preferences
There are many available forms of somatotropin in the US. 
All the current products contain the same molecule and have 
presumed comparable efficacy. However, the products differ 
in reconstitution methods, concentration of somatotropin, 
delivery device, storage requirements, preservative content, 
and time to expiration. Thus, patients/families may prefer 
one brand over another due to the ease of use with a certain 
device or convenience of longer storage. Research has 
been done on patient preferences and found that the choice 
of GH delivery device is influenced by whether or not a 
device causes bruising, has an auto-injector, and/or causes 
pain. Parents also preferred a light-weight device that is 
easy to hold, has silent delivery, and uses a ready-mixed 
drug.76 Awareness of these preferences is important, but 
the reality in choice of brand of GH treatment is that insur-
ance companies often dictate which brand or device can be 
prescribed.
Conclusions
Treatment with GH is both efficacious and safe in patients 
with GHD, TS, and all other conditions for which it is 
approved. Patients with GHD benefit from treatment whether 
or not they have an underlying organic or idiopathic   etiology. 
Patients with TS gain maximal benefit if the treatment is 
started early in childhood and continued until near-final 
height is attained. Multiple brands are available as well and all 
have similar efficacy, but physician and patient preferences, 
and insurance coverage influence the ultimate choice of GH. 
It is important to determine how the cost of treatment may 
be balanced with the effect of therapy. The marketplace for 
GH is quite competitive and we need to determine how treat-
ment can be administered in a cost-effective manner that is 
beneficial to our patients.
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